

## References

1. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol*. 2005;16:3365-3370.
2. Bellomo R, Kellum JA, Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. *Intensive Care Med*. 2007;33:409-413.
3. Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. *Crit Care Med*. 2006;34:1913-1917.
4. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. *Am J Kidney Dis*. 2002;39:930-936.
5. Carmichael P, Carmichael AR. Acute renal failure in the surgical setting. *ANZ J Surg*. 2003;73:144-153.
6. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. *Clin J Am Soc Nephrol*. 2006;1:19-32.
7. Novis BK, Roizen MF, Aronson S, Thisted RA. Association of preoperative risk factors with postoperative acute renal failure. *Anesth Analg*. 1994;78:143-149.
8. Thakar CV, Worley S, Arrigain S, et al. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. *Kidney Int*. 2005;67:1112-1119.
9. Conlon PJ, Stafford-Smith M, White WD, et al. Acute renal failure following cardiac surgery. *Nephrol Dial Transplant*. 1999;14:1158-1162.
10. Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. *Kidney Int*. 1996;50:811-818.
11. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med*. 1999;130:461-470.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16:31-41.
13. Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). *Am J Kidney Dis*. 2003;42:617-622.
14. Albright RC Jr. Acute renal failure: a practical update. *Mayo Clin Proc*. 2001;76:67-74.

15. Hilton R. Acute renal failure. *Br Med J*. 2006;333:786-790.
16. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. *Lancet*. 2005;365:417-430.
17. Singri N, Ahya SN, Levin ML. Acute renal failure. *JAMA*. 2003;289:747-751.
18. Weisbord SD, Palevsky PM. Acute renal failure in the intensive care unit. *Semin Respir Crit Care Med*. 2006;27:262-273.
19. Stevens P. Assessment of patients presenting with acute renal failure (acute kidney injury). *Medicine*. 2007;35:429-433.
20. Pépin MN, Bouchard J, Legault L, Ethier J. Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment. *Am J Kidney Dis*. 2007;50:566-573.
21. Fang LS, Sirota RA, Ebert TH, Lichtenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. *Arch Intern Med*. 1980;140:531-533.
22. Bagshaw SM, Langenberg C, Wan L, et al. A systematic review of urinary findings in experimental septic acute renal failure. *Crit Care Med*. 2007;35:1592-1598.
23. Balogun RA, Okusa MD. Diagnosis of acute tubular necrosis and prerenal disease. In: UpToDate. Rose BD, ed. UpToDate. Waltham, MA: 2008.
24. Post TP, Rose BD. Urinalysis in the diagnosis of renal disease-I. In: UpToDate. Rose BD, ed. UpToDate. Waltham, MA: 2008.
25. Zacharias M, Gilmore IC, Herbison GP, et al. Interventions for protecting renal function in the perioperative period. *Cochrane Database Syst Rev*. 2005(3):CD003590.
26. Jarnberg PO. Renal protection strategies in the perioperative period. *Best Pract Res Clin Anaesthesiol*. 2004;18:645-660.
27. Tang IY, Murray PT. Prevention of perioperative acute renal failure: what works? *Best Pract Res Clin Anaesthesiol*. 2004;18:91-111.
28. Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? *JAMA*. 2002;288:2599-2601.
29. Rahman SN, Conger JD. Glomerular and tubular factors in urine flow rates of acute renal failure patients. *Am J Kidney Dis*. 1994;23:788-793.
30. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. *Br Med J*. 2006;333:420.

31. Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. *JAMA*. 2002;288:2547-2553.
32. Lassnigg A, Donner E, Grubhofer G, et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. *J Am Soc Nephrol*. 2000;11:97-104.
33. Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. *Lancet*. 2000;356:2139-2143.
34. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. *Ann Intern Med*. 2005;142:510-524.
35. Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med*. 2001;29:1526-1531.
36. Wijeyesundera DN, Beattie WS, Rao V, et al. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. *Can J Anaesth*. 2007;54:872-881.
37. Macedo E, Abdulkader R, Castro I, et al. Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair—a randomized controlled trial. *Nephrol Dial Transplant*. 2006;21:1863-1869.
38. Ristikankare A, Kuitunen T, Kuitunen A, et al. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. *Br J Anaesth*. 2006;97:611-616.
39. Ranucci M, Soro G, Barzaghi N, et al. Fenoldopam prophylaxis of postoperative acute renal failure in high-risk cardiac surgery patients. *Ann Thorac Surg*. 2004;78:1332-1337.
40. Tumlin JA, Finkel KW, Murray PT, et al. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. *Am J Kidney Dis*. 2005;46:26-34.
41. Landoni G, Biondi-Zoccai GGL, Marino G, et al. Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. *J Cardiothorac Vasc Anesth*. 2008;22:27-33.

42. Landoni G, Biondi-Zoccai GGL, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. *Am J Kidney Dis*. 2007;49:56-68.
43. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. *AIDS*. 2004;18:351-352.
44. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. *Clin Infect Dis*. 2003;36:1070-1073.
45. Szczech LA. Tenofovir nephrotoxicity: focusing research questions and putting them into clinical context. *J Infect Dis*. 2008;197:7-9.
46. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. *Am J Med*. 1999;106:13S-24S.
47. Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. *Cleve Clin J Med*. 2002;69:289-290.
48. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. *N Engl J Med*. 1980;302:1106-1109.
49. Chambers HF. Aminoglycosides. In: Brunton LL, ed. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 11th ed. New York, NY: McGraw-Hill; 2006.
50. Raveh D, Kopyt M, Hite Y, et al. Risk factors for nephrotoxicity in elderly patients receiving once-daily aminoglycosides. *QJM*. 2002;95:291-297.
51. Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. *Ann Intern Med*. 1984;100:352-357.
52. Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. *Intensive Care Med*. 2002;28:936-942.
53. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. *J Antimicrob Chemother*. 1997;39:677-686.
54. Appel GB. Aminoglycoside nephrotoxicity. *Am J Med*. 1990;88:16S-20S.
55. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. *Am J Med*. 2001;110 (suppl 3A):33S-42S.

56. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. *Am J Epidemiol.* 2006;164:881-889.
57. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? *Am J Kidney Dis.* 2000;35:937-940.
58. Pill MW, O'Neill CV, Chapman MM, Singh AK. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. *Pharmacotherapy.* 1997;17:166-169.
59. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. *Clin Infect Dis.* 1999;29:1402-1407.
60. Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. *Kidney Int.* 2001;60:1452-1459.
61. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *N Engl J Med.* 1999;340:764-771.
62. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. *Clin Infect Dis.* 2000;31:1155-1163.
63. Deray G. Amphotericin B nephrotoxicity. *J Antimicrob Chemother.* 2002;49(suppl 1):37-41.
64. Berns JS, Cohen RM, Stumacher RJ, Rudnick MR. Renal aspects of therapy for human immunodeficiency virus and associated opportunistic infections. *J Am Soc Nephrol.* 1991;1:1061-1080.
65. Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. *Arch Intern Med.* 2003;163:402-410.
66. Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. *N Engl J Med.* 1993;328:703-706.
67. Wissmann C, Frey FJ, Ferrari P, Uehlinger DE. Acute cyclosporine-induced nephrotoxicity in renal transplant recipients: the role of the transplanted kidney. *J Am Soc Nephrol.* 1996;7:2677-2681.
68. Williams D, Haragsim L. Calcineurin nephrotoxicity. *Adv Chronic Kidney Dis.* 2006;13:47-55.

69. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. *Kidney Int.* 1993;43:706-711.
70. Kuypers DRJ, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: a prospective randomized placebo-controlled 2-year study. *Transplantation.* 2004;78:1204-1211.
71. Kamel KS, Ethier JH, Quaggin S, et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. *J Am Soc Nephrol.* 1992;2:1279-1284.
72. Stirling C, Houston J, Robertson S, et al. Diarrhoea, vomiting and ACE inhibitors: an important cause of acute renal failure. *J Hum Hypertens.* 2003;17:419-423.
73. Cruz CS, Cruz LS, Silva GR, Marcilio de Souza CA. Incidence and predictors of development of acute renal failure related to treatment of congestive heart failure with ACE inhibitors. *Nephron.* 2007;105:c77-c83.
74. Brammah A, Robertson S, Tait G, Isles C. Bilateral renovascular disease causing cardiorenal failure. *Br Med J.* 2003;326:489-491.
75. Valle R, Haragsim L. Nephrotoxicity as a complication of antiretroviral therapy. *Adv Chronic Kidney Dis.* 2006;13:314-319.
76. Taber SS, Mueller BA. Drug-associated renal dysfunction. *Crit Care Clin.* 2006;22:357-374.
77. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. *Am J Cardiol.* 2006;98:27K-36K.
78. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol.* 2004;44:1393-1399.
79. Kahn JK, Rutherford BD, McConahay DR, et al. High-dose contrast agent administration during complex coronary angioplasty. *Am Heart J.* 1990;120:533-536.
80. Schweiger MJ, Chambers CE, Davidson CJ, et al. Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. *Catheter Cardiovasc Interv.* 2007;69:135-140.
81. McCartney MM, Gilbert FJ, Murchison LE, et al. Metformin and contrast media--a dangerous combination? *Clin Radiol.* 1999;54:29-33.

82. Jain V, Sharma D, Prabhakar H, Dash HH. Metformin-associated lactic acidosis following contrast media-induced nephrotoxicity. *Eur J Anaesthesiol*. 2008;25:166-167.
83. Bush WH, Jr., Bettman MA. Update on metformin (Glucophage®) therapy and the risk of lactic acidosis: change in FDA-approved package insert. *Am Coll Radiol Bull*. 1998;54:15.
84. Benko A, Fraser-Hill M, Magner P, et al. Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. *Can Assoc Radiol J*. 2007;58:79-87.
85. Thomsen HS. Guidelines for contrast media from the European Society of Urogenital Radiology. *AJR Am J Roentgenol*. 2003;181:1463-1471.
86. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med*. 2000;343:180-184.
87. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med*. 2006;354:2773-2782.
88. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. *Euro Heart J*. 2004;25:206-211.
89. Coyle LC, Rodriguez A, Jeschke RE, et al. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. *Am Heart J*. 2006;151:1032.e1039-e1012.
90. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. *Kidney Int*. 2002;62:2202-2207.
91. Webb JG, Pate GE, Humphries KH, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. *Am Heart J*. 2004;148:422-429.
92. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. *Am J Med*. 2004;117:938-947.
93. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med*. 2008;148:284-294.
94. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. *Arch Intern Med*. 2002;162:329-336.

95. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA*. 2004;291:2328-2334.
96. Briguori C, Airoidi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. *Circulation*. 2007;115:1211-1217.
97. Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. *Clin J Am Soc Nephrol*. 2008;3:273-280.
98. Maioli M, Toso A, Leoncini M, et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. *J Am Coll Cardiol*. 2008;52:599-604.
99. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. *JAMA*. 2008;300:1038-1046.
100. Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. *J Am Coll Cardiol*. 2007;49:1283-1288.
101. Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. *Am J Cardiol*. 2007;100:781-786.
102. Attallah N, Yassine L, Musial J, et al. The potential role of statins in contrast nephropathy. *Clin Nephrol*. 2004;62:273-278.
103. Khanal S, Attallah N, Smith DE, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. *Am J Med*. 2005;118:843-849.
104. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. *Am J Cardiol*. 2008;101:279-285.
105. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. *Catheter Cardiovasc Interv*. 2002;57:279-283.
106. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. *JAMA*. 2003;290:2284-2291.

107. Michel DM, Kelly CJ. Acute interstitial nephritis. *J Am Soc Nephrol*. 1998;9:506-515.
108. Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. *Nephrol Dial Transplant*. 2004;19:8-11.
109. Eapen SS, Hall PM. Acute tubulointerstitial nephritis. *Cleve Clin J Med*. 1992;59:27-32.
110. Buysen JG, Houthoff HJ, Krediet RT, Arisz L. Acute interstitial nephritis: a clinical and morphological study in 27 patients. *Nephrol Dial Transplant*. 1990;5:94-99.
111. Lins RL, Verpooten GA, De Clerck DS, De Broe ME. Urinary indices in acute interstitial nephritis. *Clin Nephrol*. 1986;26:131-133.
112. Markowitz GS, Perazella MA. Drug-induced renal failure: a focus on tubulointerstitial disease. *Clin Chim Acta*. 2005;351:31-47.
113. Esteve JB, Launay-Vacher V, Brocheriou I, et al. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature. *Clin Nephrol*. 2005;63:385-389.
114. Rossert J. Drug-induced acute interstitial nephritis. *Kidney Int*. 2001;60:804-817.
115. Fletcher A. Eosinophiluria and acute interstitial nephritis. *N Engl J Med*. 2008;358:1760-1761.
116. Linton AL, Richmond JM, Clark WF, et al. Gallium67 scintigraphy in the diagnosis of acute renal disease. *Clin Nephrol*. 1985;24:84-87.
117. Graham GD, Lundy MM, Moreno AJ. Failure of Gallium-67 scintigraphy to identify reliably noninfectious interstitial nephritis: concise communication. *J Nucl Med*. 1983;24:568-570.
118. Clarkson MR, Giblin L, O'Connell FP, et al. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. *Nephrol Dial Transplant*. 2004;19:2778-2783.